BioCentury | Sep 21, 2018
Company News

Allergan to acquire botulinum neurotoxin play Bonti in development to treat glabellar frown lines and reduce scars following Mohs surgery; and EB-001T...
...IIa" ). Bonti Inc., Newport Beach, Calif. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Dermatology, Neurology Sandi Wong EB-001A EB-001T Allergan...
BioCentury | Aug 10, 2018
Clinical News

Bonti's EB-001A improves scar appearance following Mohs surgery in Phase IIa

Bonti Inc. (Newport Beach, Calif.) said EB-001A improved scar appearance by about 50% vs. placebo as measured by investigator-assessed visual analog scale (VAS) scores at day 30 in the Phase IIa SHINE-1 trial in 12...
BioCentury | Feb 2, 2018
Financial News

Bonti raises $15.5M in series C

Botulinum neurotoxin play Bonti Inc. (Newport Beach, Calif.) raised $15.5 million on Jan. 23 in a series C round led by existing investor City Hill Ventures. Other undisclosed new and existing investors participated. The company's...
Items per page:
1 - 3 of 3